Every material Form 8-K Azenta filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On October 28, 2026, Azenta entered a license agreement and a supply agreement with Elegen Corp. for cell-free DNA synthesis technology, and acquired all outstanding stock of SynPlexity Inc., a DNA assembly technology company. The company expects aggregate capital deployment under the Elegen agreements of approximately $32 million to $71 million, depending on future equipment purchases and whether it converts the license to a perpetual one. The filing gives no revenue, profit, or guidance figures, so its direct effect on results is not quantified.
Elegen license is exclusive and royalty-free for specified gene synthesis products, with an initial term of five years.
Azenta has an option, exercisable 12 to 18 months after execution, to convert the license to a perpetual exclusive one for $25 million plus any unpaid license fees.
Expected aggregate capital deployment under the Elegen agreements is approximately $32 million to $71 million.
SynPlexity acquisition closed concurrently with signing on October 28, 2026; the filing does not state the purchase price.
Azenta said its board approved a restructuring plan on October 5, 2026, to consolidate its North American laboratory network, cut workforce and close three Multiomics sites in North America. The company estimates $11.0 million to $13.0 million in pre-tax charges, mostly non-cash impairments, with about $7.0 million in future cash spending and about $11.0 million in annualized savings once fully implemented.
Plan approved October 5, 2026, within the Multiomics segment; employee notifications began October 6, 2026
Estimated pre-tax charges of $11.0 million to $13.0 million, including about $9.0 million of asset impairment and about $3.0 million of severance and other restructuring
Estimated future cash expenditures of about $7.0 million; expected annualized cost savings of about $11.0 million
Most charges expected in the fiscal year ending September 30, 2027; actions substantially complete by March 31, 2027
Azenta's board approved a letter agreement with Dr. Martin D. Madaus, its Interim President and Chief Executive Officer since August 22, 2026, setting his base salary, a cash performance bonus, and an equity grant. The company also granted retention restricted stock units to four named executive officers, including $1,000,000 for Chief Financial Officer Lawrence Lin. The filing discloses pay terms and governance changes, and it does not report financial results.
Madaus receives an annual base salary of $600,000 and a cash performance recognition bonus equal to 100% of salary, which vests on the first anniversary of his start date.
Madaus receives restricted stock units with an award value of $1,200,000, vesting in 1/12 monthly installments from his start date.
Retention awards: Lawrence Lin $1,000,000; Ephraim Starr, Olga Pirogova and Trey Martin $500,000 each, with 50% vesting on each of the first and second anniversaries of the September 14, 2026 grant date.
Madaus left the Nominating and Governance Committee, which now consists of William L. Cornog (Chair), Frank E. Casal and Robyn C. Davis.
Azenta's President and CEO John Marotta resigned from the company and its Board effective August 22, 2026, and the Board named director Dr. Martin Madaus as interim President and CEO. The company reaffirmed its fourth quarter fiscal 2026 total revenue guidance but expects a one-time approximately $3 million consulting expense to affect fourth quarter adjusted EBITDA, and a search for a permanent CEO is underway.
John P. Marotta resigned as President, CEO and director effective August 22, 2026; the company says the resignation was not due to any disagreement on operations, policies or practices.
Dr. Martin D. Madaus, a Board member since January 2024, was elected interim President and CEO effective August 22, 2026, and will step down from the Nominating and Governance Committee chair role.
Fourth quarter fiscal 2026 total revenue guidance, issued August 4, 2026, was reaffirmed; adjusted EBITDA will be affected by a one-time approximately $3 million consulting expense.
The Board reduced its size from nine to eight members, and the company has retained Heidrick & Struggles to search for a permanent CEO.
Azenta, Inc. appointed Erik J. Bello as Vice President and Chief Accounting Officer, with his employment expected to begin August 31, 2026. CFO Lawrence Lin will stop serving as principal accounting officer on that date but will remain Executive Vice President and Chief Financial Officer. The filing describes a routine accounting leadership change with no financial results included.
Erik J. Bello, age 51, was appointed by the Board on August 6, 2026; employment expected to start August 31, 2026
Bello's offer letter sets a $380,000 annual base salary and an $80,000 one-time sign-on bonus
Bello's incentive target is 50% of base salary, with long-term awards of $150,000 for the current fiscal year and $300,000 for the following year
Lawrence Lin ceases as principal accounting officer but remains CFO
Azenta reported third-quarter fiscal 2026 revenue from continuing operations of $161 million, up 12% from a year earlier, with organic growth of 9%. Continuing-operations diluted EPS was $(0.03) versus $(0.01) a year ago, and the company narrowed its full-year revenue and adjusted EBITDA ranges, so shareholders see higher sales alongside a wider per-share loss from continuing operations.
Revenue was $161 million, up 12% year over year; organic revenue rose 9%, and Sample Management Solutions revenue rose 14% to $88 million.
Diluted EPS from continuing operations was $(0.03) versus $(0.01) a year earlier; total diluted EPS was $0.05; non-GAAP diluted EPS was $0.16 versus $0.17.
Full-year fiscal 2026 revenue guidance is $613 million to $618 million, versus prior $603 million to $621 million; adjusted EBITDA guidance is $59 million to $62 million.
As of June 30, 2026, the company had repurchased $50.0 million of stock under a $250 million program authorized December 8, 2025.
Azenta said it completed the sale of B Medical Systems to Thelema S.à r.l. on July 1, 2026, for a fixed $63 million, of which $28 million was paid in cash and $35 million was funded by a secured vendor loan to Thelema. The filing states that Thelema is majority owned by Luc Provost, a Vice President of Azenta and CEO of B Medical, and that the Audit Committee approved the arrangements as a related-party transaction. The pro forma balance sheet shows a $41.5 million reduction to retained earnings tied to cumulative translation adjustments and estimated cost to sell.
Purchase price: $63 million fixed, with no customary post-closing adjustments; $28 million cash and a $35 million vendor loan
Vendor loan to Thelema: $35 million at 6.0% interest, maturing three months after funding, secured by a first-priority pledge over B Medical equity
Related-party transaction: Thelema is majority owned by Luc Provost, a Vice President of Azenta and CEO of B Medical; Audit Committee approved
The transaction had not closed by March 31, 2026, due to Thelema's inability to secure financing at that time
Azenta reported fiscal second-quarter 2026 revenue of $145 million, up 1% year over year, but organic revenue fell 3% and the company recorded a $149 million non-cash goodwill impairment, producing a diluted loss of $3.41 per share from continuing operations. Azenta also lowered its fiscal 2026 guidance, now expecting organic revenue of down about 2% to up 1% versus prior growth of 3% to 5%, and extended its long-range plan to 2029. The $63 million sale of B Medical Systems has not closed because the buyer has not secured financing.
Q2 revenue was $145 million, up 1% year over year; organic revenue declined 3%
Diluted EPS from continuing operations was ($3.41) versus ($0.43) a year earlier, including a $149 million goodwill impairment
FY2026 organic revenue now expected to range from down about 2% to up 1%, versus prior guidance of 3% to 5% growth
Adjusted EBITDA margin now expected to fall about 125 basis points to flat; B Medical Systems $63 million sale did not close by March 31, 2026
Azenta, Inc. said William 'Trey' E. Martin III became president of its Multiomics business effective April 6, 2026, replacing Ginger Zhou, who stepped down the same day and will advise the company through November 2026. Martin's offer letter sets a $540,000 base salary and a target bonus of 80% of base, with equity awards subject to Board approval. The company said the change is aimed at accelerating execution of the Multiomics long-range plan presented at its December 2025 Investor Day, and the filing also amends change-in-control severance terms for three executive officers.
Trey Martin became President, Multiomics, effective April 6, 2026, reporting to CEO John Marotta; he was CEO of Maravai LifeSciences from July 2023 to June 2025.
Ginger Zhou stepped down April 6, 2026, stating no disagreement with the company; she will advise through November 2026 under a consulting fee of $103,500.
Martin's offer letter: $540,000 base salary, 80% target bonus, target equity of about $1.7 million plus a one-time performance award of about $500,000, subject to Board approval.
Martin's non-change-in-control severance is 12 months of salary continuation, subject to a release of claims.
On March 4, 2026, Azenta's UK subsidiary acquired UK Biocentre Limited, a UK provider of sample management and storage services, for GBP 20.5 million net of cash, including up to GBP 1.8 million in milestone-based contingent consideration. Azenta expects the deal to reduce its 2026 Adjusted EBITDA margin on a pro forma basis, while adding to its 2027 and 2028 organic revenue growth and margin expansion expectations.
Total consideration of GBP 20.5 million, net of cash, including up to GBP 1.8 million contingent on milestones
UK Biocentre generated about GBP 15.3 million in revenue for the twelve months ended September 30, 2025
Expected to be dilutive to 2026 Adjusted EBITDA margin by about 35 basis points on a pro forma fiscal-year basis
Expected to be accretive to 2027 and 2028 organic revenue growth and Adjusted EBITDA margin expansion expectations
Azenta reported fiscal first-quarter 2026 results for the quarter ended December 31, 2025, with revenue of $149 million, up 1% year over year, but organic revenue declined 1%. Profitability weakened: non-GAAP diluted EPS was $0.09 versus $0.12 a year earlier, adjusted EBITDA fell to $13 million, and gross margin dropped to 42.9%. Management reiterated its fiscal 2026 guidance, which matters to shareholders because it signals the company still expects a stronger second half despite the margin pressure.
Revenue was $149 million, up 1% year over year; organic revenue declined 1%.
GAAP diluted EPS from continuing operations was ($0.11) versus ($0.16); total diluted EPS was ($0.34) including discontinued operations.
Non-GAAP diluted EPS was $0.09 versus $0.12, and adjusted EBITDA margin was 8.5% versus 10.8%.
Fiscal 2026 guidance reiterated: organic revenue growth of 3% to 5% and adjusted EBITDA margin expansion of approximately 300 basis points; the $63 million B Medical Systems sale is expected to close on or before March 31, 2026.
Azenta, Inc. disclosed that director Alan P. Malus resigned from its Board of Directors effective January 29, 2026. The company said the resignation was not due to any disagreement and that Malus has taken a full-time role with another company that will limit his time for Azenta duties.
Alan P. Malus resigned from the Board effective January 29, 2026
He also served on the Human Resources and Compensation Committee
Company states no disagreement with Azenta or its Board on operations, policies, or practices
Resignation attributed to Malus assuming full-time responsibilities at another company
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Azenta filing is on SEC EDGAR ↗. 8-K briefs of other companies →